HBV相关慢加急性肝衰竭前期概念及诊疗新进展*

doi:10.3969/j.issn.1672-5069.2015.01.030

Abstract

Abstract: Hepatitis B virus （HBV）-related acute-on-chronic liver failure （ACLF）,characterized by rapid disease progression and high mortality,is a serious health problem in China. The outcomes will differ if the clinicians can diagnose the patients with ACLF in time and give them instant intervention. So some scholars in the world began to study the patients in so-called pre-liver failure stage. The scholars in the west,Hong Kong and Taiwan defined it as severe acute exacerbation of chronic hepatitis B,while the scholars in the mainland tried to set up three different diagnostic criteria for pre-ACLF. This review mainly focuses on recent advances in the definition, diagnosis and treatment of patients with HBV-related pre-ACLF.

Key words: Hepatitis B, Liver failure, Pre-stage, Diagnosis, Treatment

Li Chen, You Shaoli, Xin Shaojie. What's new The definition,diagnosis and management of HBV-related pre- acute-on-chronic liver failure[J]. JOURNAL OF PRACTICAL HEPATOLOGY, 2015, 18(1): 105-108.

References

[1] 中华医学会肝病学分会和感染病学分会.慢性乙型肝炎防治指南（2010年版）. 实用肝脏病杂志,2011,14（2）：81-89.
[2] European Association for the Study of the Liver. EASL clinical practice guidelines:Management of chronic hepatitis B virus infection. J Hepatol,2012,57（1）:167-185.
[3] 中华医学会感染病学分会肝衰竭与人工肝学组和肝病学分会重型肝病与人工肝学组.肝衰竭诊治指南.实用肝脏病杂志,2013,16（3）：210-216.
[4] Sarin SK,Kumar A,Almeida JA,et al. Acute-on-chronic liver failure:consensus recommendations of the Asian Pacific Association for the study of the liver （APASL）. Hepatol Int,2009,3（1）:269-282.
[5] Moreau R,Jalan R,Gines P,et al. Acute-on-chronic liver failure is a distinct syndrome that develops in patients with acute decompensation of cirrhosis. Gastroenterology,2013,144（7）:1426-1437.
[6] Yu S,Jianqin H,Wei W,et al. The efficacy and safety of nucleos（t）ide analogues in the treatment of HBV-related acute-on-chronic liver failure:a meta-analysis. Ann Hepatol,2013,12（3）:364-372.
[7] Zheng Z,Li X,Li Z,et al. Artificial and bioartificial liver support systems for acute and acute-on-chronic hepatic failure:A meta-analysis and meta-regression. Exp Ther Med,2013,6（4）:929-936.
[8] Xu X,Liu X,Ling Q,et al. Artificial liver support system combined with liver transplantation in the treatment of patients with acute-on-chronic liver failure. PLoS One,2013,8（3）:e58738.
[9] 杨晓鲲,徐贵森. 糖皮质激素治疗乙型肝炎病毒相关性肝衰竭疗效的Meta分析. 解放军医学杂志,2013,38（7）:581-585.
[10] Kamath PS,Wiesner RH,Malinchoc M,et al. A model to predict survival in patients with end-stage liver disease. Hepatology,2001,33（2）:464-470.
[11] Biggins SW,KimWR,TerraultNA,et al. Evidence-based incorporation of serum sodium concentration into MELD. Gastroenterology,2006,130（6）:1652-1660.
[12] Luca A,Angermayr B,Bertolini G,et al. An integrated MELD model including serum sodium and age improves the prediction of early mortality in patients with cirrhosis. Liver Transpl,2007,13（8）:1174-1180.
[13] 林贤丰,李凌菲,俞燮琰,等. MELD相关评分体系对乙型肝炎相关慢加急性肝衰竭患者预后的预测价值. 中华临床医师杂志（电子版）,2012,6（19）: 5853-5857.
[14] 李晨,游绍莉,刘鸿凌,等.基线MELD、MELD-Na、iMELD3种模型对乙型肝炎病毒相关慢加急性肝衰竭患者近期预后的评估价值.中华危重病急救医学,2014, 26（8）:6-10.
[15] 骆欣,朱国献,刘惠敏,等.753例重型肝炎病原学及预后相关因素分析. 医学研究杂志,2011,40（2）:96-98.
[16] 汤伟亮,赵钢德,董志霞,等. 肝衰竭预后危险因素及预后模型建立的研究. 传染病信息,2011,24（3）:159-162.
[17] Garg H,Kumar A,Garg V,et al. Hepatic and systemic hemodynamic derangements predict early mortality and recovery in patients with acute-on-chronic liver failure. J Gastroenterol Hepatol,2013,28（8）:1361-1367.
[18] Wong VW,Chan HL. Severe acute exacerbation of chronic hepatitis B:a unique presentation of a common disease. J Gastroenterol Hepatol,2009,24（7）:1179-1186.
[19] Chien RN,Lin CH,Liaw YF. The effect of lamivudine therapy in hepatic decompensation during acute exacerbation of chronic hepatitis B. J Hepatol,2003,38（3）:322-327.
[20] Chan HL,Tsang SW,Hui Y,et al. The role of lamivudine and predictors of mortality in severe flare-up of chronic hepatitis B with jaundice. J Viral Hepat,2002,9（6）:424-428.
[21] Yuen MF,Sablon E,Hui CK,et al. Prognostic factors in severe exacerbation of chronic hepatitis B. Clin Infect Dis,2003,36（8）:979-984.
[22] Tsubota A,Arase Y,Suzuki Y,et al. Benefit of lamivudine therapy and factors associated with clinical outcome in spontaneous severe acute exacerbation of chronic hepatitis B virus infection. Intervirology,2004,47（6）:335-341.
[23] Mao Q,Zhang HY,You JP,et al. Severe acute exacerbation of chronic hepatitis B during pegylated interferon treatment and early intervention with corticosteroid. Virol J,2012,9:136.
[24] Fujiwara K,Yasui S,Okitsu K,et al. The requirement for a sufficient period of corticosteroid treatment in combination with nucleoside analogue for severe acute exacerbation of chronic hepatitis B. J Gastroenterol,2010,45（12）:1255-1262.
[25] Fujiwara K,Yasui S,Yonemitsu Y,et al. Efficacy of combination therapy of antiviral and immunosuppressive drugs for the treatment of severe acute exacerbation of chronic hepatitis B. J Gastroenterol,2008,43（9）:711-719.
[26] Tsubota A,Arase Y,Suzuki Y,et al. Lamivudine monotherapy for spontaneous severe acute exacerbation of chronic hepatitis B. J Gastroenterol Hepatol,2005,20（3）:426-432.
[27] Chien RN,Lin CH,Liaw YF. The effect of lamivudine therapy in hepatic decompensation during acute exacerbation of chronic hepatitis B. J Hepatol,2003,38（3）:322-327.
[28] Chan HL,Wong VW,Hui AY,et al. Long-term lamivudine treatment is associated with a good maintained response in severe acute exacerbation of chronic HBeAg-negative hepatitis B. Antivir Ther,2006,11（4）:465-471.
[29] Wong VW,Wong GL,Tsang SW,et al. Long-term follow-up of lamivudine treatment in patients with severe acute exacerbation of hepatitis B e antigen （HBeAg）-positive chronic hepatitis B. Antivir Ther,2008,13（4）:571-579.
[30] Wong VW,Wong GL,Yiu KK,et al. Entecavir treatment in patients with severe acute exacerbation of chronic hepatitis B. J Hepatol,2011,54（2）:236-242.
[31] Tsai WL,Chiang PH,Chan HH,et al. Early entecavir treatment for chronic hepatitis B with severe acute exacerbation. Antimicrob Agents Chemother,2014,58（4）:1918-1921.
[32] Chen CH,Lin CL,Hu TH,et al. Entecavir vs. lamivudine in chronic hepatitis B patients with severe acute exacerbation and hepatic decompensation. J Hepatol,2014,60（6）:1127-1134.
[33] 刘明,张绪清,毛青. 慢加急性肝衰竭前期的概念及预警模型. 临床肝胆病杂志,2012,28（10）:732-734.
[34] 刘明,邓国宏,谭顺,等. 慢加急性肝衰竭前期临床常规预警指标研究. 第三军医大学学报,2012,34（8）:772-775.
[35] Zhang XQ,Jiang L,You JP,et al. Efficacy of short-term dexamethasone therapy in acute-on-chronic pre-liver failure. Hepatol Res,2011,41（1）:46-53.
[36] Xia Q, Dai X,Zhang Y,et al. A modified MELD model for Chinese pre-ACLF and ACLF patients and it reveals poor prognosis in pre-ACLF patients. PLoS One,2013,8（6）:e64379.

What's new The definition,diagnosis and management of HBV-related pre- acute-on-chronic liver failure

PDF (PC)

Knowledge

Abstract

Cite this article

share this article

References

Related Articles 15

Recommended Articles

Metrics

Comments

[1]	National Workshop on Fatty Liver, Alcoholic Liver Disease, Chinese Society of Hepatology; National Workshop on Liver, Metabolism, Chinese Society of Endocrinology, Chinese Medical Association. Committee of Hepatology, Chinese Research Hospital Association; Fatty Liver Expert Committee, Chinese Medical Doctor Association [J]. Journal of Practical Hepatology, 2019, 22(6): 787-792.
[2]	. Consensus on the diagnosis and therapy of hepatic fibrosis [J]. Journal of Practical Hepatology, 2019, 22(6): 793-803.
[3]	chronic hepatitis B Zhu Lingyun, Zhang Maohai Cui Shasha, et al.. Serum IL-12 and IL-18 levels as well as peripheral blood mononuclear cell FOXp3 in patients with [J]. Journal of Practical Hepatology, 2019, 22(6): 816-819.
[4]	Shi Yingying, Wang Yuanxi.. Impact of combination telbivudine and adefovir dipivoxil on renal functions in the treatment of patients with chronic hepatitis B [J]. Journal of Practical Hepatology, 2019, 22(6): 820-823.
[5]	Min Feng, Huang Wenqi, Wu Weibing, et al.. Implications of serum adipocytokine levels in patients with chronic hepatitis B [J]. Journal of Practical Hepatology, 2019, 22(6): 824-827.
[6]	patients with chronic hepatitis B Zhang Yingming, Shen Shuang, Tian Fei, et al.. Prediction of response to peginterferon alfa-2a by blood IFNL4 and IL-28B gene polymorphisms in [J]. Journal of Practical Hepatology, 2019, 22(6): 828-831.
[7]	chronic hepatitis B virus carriers Wu Haiyi, Chen Jianxin.. Diagnostic efficacy of four non-invasive diagnostic models in evaluating significant liver fibrosis in [J]. Journal of Practical Hepatology, 2019, 22(6): 832-835.
[8]	Ma Liying, Shen Lijuan.. Efficacy and safety of tenofovir in the treatment of pregnant women with high HBV DNA loads [J]. Journal of Practical Hepatology, 2019, 22(6): 836-839.
[9]	Cao Ce, Yu Yixing, Wang Beibei, et al.. Clinical diagnostic efficacy of enhanced magnetic resonance imaging combined with serum AFP and PIVKA-Ⅱ in the diagnosis of patients with hepatocellular carcinoma [J]. Journal of Practical Hepatology, 2019, 22(6): 896-899.
[10]	Zeng Yanni, Zhang Can, Bi Junying, et al.. Value of long-time delayed enhancement scan of MRI in the diagnosis of solitary necrotic nodule of liver [J]. Journal of Practical Hepatology, 2019, 22(6): 900-903.
[11]	Li Chuanjie, Xu Jing, Wang Liangliang, et al.. Changes of serum HBsAg levels in patients with chronic hepatitis B receiving entecavir treatment [J]. Journal of Practical Hepatology, 2019, 22(6): 928-929.
[12]	Zhang Rui, Wang Jian, Chen Shiyao.. Mechanism of portal vein thrombosis in cirrhotic patients with portal hypertension and the treatment [J]. Journal of Practical Hepatology, 2019, 22(6): 930-933.
[13]	Xing Hao, Han Jun, Yang Tian.. Diagnostic value of serum protein induced by vitamin K absence or antagonist II for hepatocellular carcinoma [J]. Journal of Practical Hepatology, 2019, 22(6): 934-937.
[14]	Liang Jubo, Miao Qi, Ma Xiong.. Diagnosis and treatment of cholangiocytic cholestasis [J]. Journal of Practical Hepatology, 2019, 22(6): 941-943.
[15]	Du Keye, Yang Dongliang, Liu Jia. Regulatory T cells in hepatitis B [J]. Journal of Practical Hepatology, 2019, 22(5): 613-616.